Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The Synergistic Effects of Co-Treatment with Glucagon-Like Peptide-1 and -2 Receptor Agonists on Glucose Metabolism and Intestinal Growth/Function.

EF 2019-20

Résumé
"The gastrointestinal tract secretes substances that regulate metabolic homeostasis. Specifically, the L cells, located within the distal portion of the small intestine and the colon, secrete Glucagon-Like Peptide-1 (GLP-1) and -2 (GLP-2) in response to food intake. Exenatide (Ex-4) is a mimic of GLP-1, and is approved for the treatment of type 2 diabetes (T2D) and obesity due to its positive effects on glucose metabolism and food intake. Conversely, teduglutide is a GLP-2 mimic that is used to treat patients with short bowel syndrome (SBS), who are missing parts of their small and/or large intestines, as it stimulates intestinal growth and food absorption. Interestingly, these peptides have been shown to have overlapping functions, prompting great interest in engineering a new peptide that, by combining both GLP-1 and 2's effects, can drastically improve upon the current treatment regimen for T2D/Obesity and SBS. By combining both functionalities, it is not only possible for the beneficial effects to be additive, but the potential drug may also exhibit synergism- a phenomenon in which both drugs in combination interact to produce an effect greater than what would be expected if their effects were summed individually. This project aims to investigate the potential presence/absence of synergism here by administering GLP-1 and 2 mimics to mice both alone and in combination. As synergism is dependent on doses, various dosing combinations of both peptides will be studied. By investigating the various doses at which synergy may occur in between GLP-1 and 2, this study has the potential to help inform the engineering of combined GLP1/2 mimics tailored for T2D/Obesity and SBS. "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
429063
Name
Srikrishnaraj Arjuna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Synergistic Effects of Co-Treatment with Glucagon-Like Peptide-1 and -2 Receptor Agonists on Glucose Metabolism and Intestinal Growth/Function.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Glucagon-Like Peptide-1; Glucagon-Like Peptide-2; Glucose Metabolism; Intestinal Growth And Function; Intestinal Permeability; Obesity; Pancreas; Short Bowel Syndrome; Synergistic Interactions; Type 2 Diabetes
Abstract
"The gastrointestinal tract secretes substances that regulate metabolic homeostasis. Specifically, the L cells, located within the distal portion of the small intestine and the colon, secrete Glucagon-Like Peptide-1 (GLP-1) and -2 (GLP-2) in response to food intake. Exenatide (Ex-4) is a mimic of GLP-1, and is approved for the treatment of type 2 diabetes (T2D) and obesity due to its positive effects on glucose metabolism and food intake. Conversely, teduglutide is a GLP-2 mimic that is used to treat patients with short bowel syndrome (SBS), who are missing parts of their small and/or large intestines, as it stimulates intestinal growth and food absorption. Interestingly, these peptides have been shown to have overlapping functions, prompting great interest in engineering a new peptide that, by combining both GLP-1 and 2's effects, can drastically improve upon the current treatment regimen for T2D/Obesity and SBS. By combining both functionalities, it is not only possible for the beneficial effects to be additive, but the potential drug may also exhibit synergism- a phenomenon in which both drugs in combination interact to produce an effect greater than what would be expected if their effects were summed individually. This project aims to investigate the potential presence/absence of synergism here by administering GLP-1 and 2 mimics to mice both alone and in combination. As synergism is dependent on doses, various dosing combinations of both peptides will be studied. By investigating the various doses at which synergy may occur in between GLP-1 and 2, this study has the potential to help inform the engineering of combined GLP1/2 mimics tailored for T2D/Obesity and SBS. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Srikrishnaraj, Arjuna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~